EDITAS MEDICINE, INC. Equity Securities, FV-NI, Unrealized Gain
EDITAS MEDICINE, INC. (EDIT) reported Equity Securities, FV-NI, Unrealized Gain of $13.11 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2021-11-09
- EDITAS MEDICINE, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2020-09-30 was -$1.42M.
- EDITAS MEDICINE, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2020-06-30 was $7.19M.
- EDITAS MEDICINE, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2020-03-31 was $7.33M.
| Period end | Equity Securities, FV-NI, Unrealized Gain 3 month | Equity Securities, FV-NI, Unrealized Gain 6 month | Equity Securities, FV-NI, Unrealized Gain 9 month |
|---|---|---|---|
| 2020-09-30 | -$1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $5.78M derived: sum of 2 quarters · filed 2021-11-09 | $13.11M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $7.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $14.53M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $7.33M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |